Revenue Summary of Cosmo Pharmaceuticals N.V.

Cosmo Pharmaceuticals N.V.'s latest annual revenue in 2023 was 92.78 Million EUR , down -9.12% from previous year.
Cosmo Pharmaceuticals N.V.'s latest quarterly revenue in 2024 Q2 was 68.11 Million EUR , down 0.0% from previous quarter.
Cosmo Pharmaceuticals N.V. reported a annual revenue of 102.08 Million EUR in annual revenue 2022, up 56.88% from previous year.
Cosmo Pharmaceuticals N.V. reported a annual revenue of 65.07 Million EUR in annual revenue 2021, up 6.77% from previous year.
Cosmo Pharmaceuticals N.V. reported a quarterly revenue of 68.11 Million EUR for 2024 Q2, down 0.0% from previous quarter.
Cosmo Pharmaceuticals N.V. reported a quarterly revenue of 21.83 Million EUR for 2023 Q2, down 0.0% from previous quarter.

Annual Revenue Chart of Cosmo Pharmaceuticals N.V. (2023 - 2004)

Historical Annual Revenue of Cosmo Pharmaceuticals N.V. (2023 - 2004)

Year	Revenue	Revenue Growth
2023	92.78 Million EUR	-9.12%
2022	102.08 Million EUR	56.88%
2021	65.07 Million EUR	6.77%
2020	60.94 Million EUR	-2.47%
2019	62.49 Million EUR	-4.76%
2018	65.61 Million EUR	-2.42%
2017	67.24 Million EUR	-0.62%
2016	67.66 Million EUR	11.64%
2015	60.6 Million EUR	-23.85%
2014	79.59 Million EUR	41.2%
2013	56.36 Million EUR	-5.32%
2012	59.53 Million EUR	77.67%
2011	33.5 Million EUR	4.55%
2010	32.05 Million EUR	20.1%
2009	26.68 Million EUR	-21.91%
2008	34.17 Million EUR	56.04%
2007	21.9 Million EUR	44.48%
2006	15.15 Million EUR	-2.24%
2005	15.5 Million EUR	40.58%
2004	11.03 Million EUR	0.0%

Year	Revenue	Revenue Growth
2024 Q1	68.11 Million EUR	177.36%
2024 Q2	68.11 Million EUR	0.0%
2023 Q2	21.83 Million EUR	0.0%
2023 Q3	24.55 Million EUR	12.5%
2023 FY	92.78 Million EUR	-9.12%
2023 Q4	24.55 Million EUR	0.0%
2023 Q1	21.83 Million EUR	-27.93%
2022 Q3	30.28 Million EUR	45.93%
2022 Q1	20.75 Million EUR	13.25%
2022 FY	102.08 Million EUR	56.88%
2022 Q4	30.28 Million EUR	0.0%
2022 Q2	20.75 Million EUR	0.0%
2021 FY	65.07 Million EUR	6.77%
2021 Q2	14.21 Million EUR	0.0%
2021 Q1	14.21 Million EUR	-18.95%
2021 Q3	18.32 Million EUR	28.97%
2021 Q4	18.32 Million EUR	0.0%
2020 Q1	12.94 Million EUR	-36.85%
2020 Q4	17.53 Million EUR	0.0%
2020 FY	60.94 Million EUR	-2.47%
2020 Q3	17.53 Million EUR	35.48%
2020 Q2	12.94 Million EUR	0.0%
2019 Q2	10.75 Million EUR	0.0%
2019 Q3	20.49 Million EUR	90.58%
2019 FY	62.49 Million EUR	-4.76%
2019 Q1	10.75 Million EUR	-25.19%
2019 Q4	20.49 Million EUR	0.0%
2018 Q3	14.37 Million EUR	-22.02%
2018 FY	65.61 Million EUR	-2.42%
2018 Q2	18.43 Million EUR	0.0%
2018 Q1	18.43 Million EUR	3.43%
2018 Q4	14.37 Million EUR	0.0%
2017 Q3	17.82 Million EUR	11.14%
2017 FY	67.24 Million EUR	-0.62%
2017 Q4	17.82 Million EUR	0.0%
2017 Q2	16.03 Million EUR	0.0%
2017 Q1	16.03 Million EUR	-12.7%
2016 Q1	15.82 Million EUR	-22.07%
2016 FY	67.66 Million EUR	11.64%
2016 Q4	18.36 Million EUR	0.0%
2016 Q3	18.36 Million EUR	16.04%
2016 Q2	15.82 Million EUR	0.0%
2015 Q3	20.31 Million EUR	103.1%
2015 Q4	20.31 Million EUR	0.0%
2015 Q1	10 Million EUR	-48.1%
2015 FY	60.6 Million EUR	-23.85%
2015 Q2	10 Million EUR	0.0%
2014 FY	79.59 Million EUR	41.2%
2014 Q4	19.27 Million EUR	0.0%
2014 Q3	19.27 Million EUR	-6.21%
2014 Q1	20.54 Million EUR	33.37%
2014 Q2	20.54 Million EUR	0.0%
2013 Q1	13.28 Million EUR	41.11%
2013 Q2	13.28 Million EUR	0.0%
2013 Q3	15.4 Million EUR	15.95%
2013 Q4	15.4 Million EUR	0.0%
2013 FY	56.36 Million EUR	-5.32%
2012 FY	59.53 Million EUR	77.67%
2012 Q1	14.88 Million EUR	0.0%
2012 Q2	14.88 Million EUR	0.0%
2012 Q4	9.41 Million EUR	0.0%
2012 Q3	9.41 Million EUR	-36.73%
2011 Q4	14.88 Million EUR	77.67%
2011 FY	33.5 Million EUR	4.55%
2011 Q2	8.37 Million EUR	0.0%
2011 Q1	8.37 Million EUR	0.0%
2011 Q3	8.37 Million EUR	0.0%
2010 Q4	8.37 Million EUR	4.55%
2010 FY	32.05 Million EUR	20.1%
2010 Q3	8.01 Million EUR	0.0%
2010 Q2	8.01 Million EUR	0.0%
2010 Q1	8.01 Million EUR	0.0%
2009 Q2	6.67 Million EUR	0.0%
2009 Q4	8.01 Million EUR	20.1%
2009 Q3	6.67 Million EUR	0.0%
2009 FY	26.68 Million EUR	-21.91%
2009 Q1	6.67 Million EUR	0.0%
2008 Q2	8.54 Million EUR	0.0%
2008 Q1	8.54 Million EUR	0.0%
2008 FY	34.17 Million EUR	56.04%
2008 Q4	6.67 Million EUR	-21.91%
2008 Q3	8.54 Million EUR	0.0%
2007 Q4	8.54 Million EUR	56.04%
2007 Q3	5.47 Million EUR	0.0%
2007 Q2	5.47 Million EUR	0.0%
2007 Q1	5.47 Million EUR	0.0%
2007 FY	21.9 Million EUR	44.48%
2006 FY	15.15 Million EUR	-2.24%
2006 Q1	3.78 Million EUR	0.0%
2006 Q4	5.47 Million EUR	44.48%
2006 Q2	3.78 Million EUR	0.0%
2006 Q3	3.78 Million EUR	0.0%
2005 Q2	3.87 Million EUR	0.0%
2005 Q3	3.87 Million EUR	0.0%
2005 Q4	3.78 Million EUR	-2.24%
2005 FY	15.5 Million EUR	40.58%
2005 Q1	3.87 Million EUR	0.0%
2004 Q4	3.87 Million EUR	40.58%
2004 FY	11.03 Million EUR	0.0%
2004 Q2	2.75 Million EUR	0.0%
2004 Q1	2.75 Million EUR	0.0%
2004 Q3	2.75 Million EUR	0.0%
2003 Q4	2.75 Million EUR	0.0%

Peer Revenue Comparison of Cosmo Pharmaceuticals N.V.

Name	Revenue	Revenue Difference
Relief Therapeutics Holding AG	6.03 Million CHF	-1437.875%
Tecan Group AG	1.07 Billion CHF	91.364%
Santhera Pharmaceuticals Holding AG	103.41 Million CHF	10.283%
Basilea Pharmaceutica AG	157.63 Million CHF	41.142%
Bachem Holding AG	577.31 Million CHF	83.929%
Siegfried Holding AG	1.27 Billion CHF	92.703%
Molecular Partners AG	7.03 Million CHF	-1218.272%

Global Stocks Search

Cosmo Pharmaceuticals N.V. (0RGI.L)

Revenue Summary of Cosmo Pharmaceuticals N.V.

Annual Revenue Chart of Cosmo Pharmaceuticals N.V. (2023 - 2004)

Historical Annual Revenue of Cosmo Pharmaceuticals N.V. (2023 - 2004)

Peer Revenue Comparison of Cosmo Pharmaceuticals N.V.